Latest Articlesddd
GlaxoSmithKline and Innoviva: The COPD inhaler Relvar® Ellipta® (known as Brio Ellipta in the United States) …
Yes, indeed, the good news has come from the randomized CABOSUN phase 2 trial with Exelixis’ …
CANCER Everyday something new is discovered that explains cancer behavior, including proliferation, response to treatment, resistance …
Notwithstanding the unrelenting improvements being constantly made in managing blood coagulation’s problems, conventional anticoagulants still have …
COLLABORATIONS Preparing for the Future, Biogen Signs a Lucrative Collaborative Agreements While Highlighting the Small Firm …
Underestimating the Value of Drugs that Disrupt the DNA Repair Mechanisms in Cancer Cells. AstraZeneca’s (AZN) Chief …
Seres Therapeutics (MCRB), is microbiome therapeutics platform company. It focuses on developing a novel class of …
GILEAD After years of controversial refraining, official India reversed course and granted Gilead Sciences its patent …
By June, which is next month, Incyte (INCY) will be the owner of the European operations …
EXELIXIS AGAIN They said: Sell EXEL, as no partner is interested in the firm’s FDA approved …
Prohost Letter #395 On the Road TO DEFEATING CANCER - Results of cancer treatment with novel immunotherapy …
GILEAD SCIENCES The people who cause the selloff of Gilead’s (GILD) stock because it missed 5 …
Medivation is a Target for Acquisition The Question is: Who Will Acquire Medivation? Sanofi has made a bid …
Biotech NEWS AGENUS Agenus’ First Checkpoint Inhibitor to reach Clinical Trial The first patient has …
Congratulations. The FDA approved Exelixis’ (EXEL) drug Cabometyx™ (cabozantinib) tablets for advanced renal cell carcinoma …
The AACR 2016 meeting presentations differed substantially from previous meetings. The 2016 meeting has brought near …
Illumina Showing 6% revenue increase over the same quarter last year, Q1 2016, was not enough as Illumina …
Meaningful Presentations at the Annual Meeting of the American Association for Cancer Research (AACR) NEKTAR THERAPEUTICS …
In the biotech sector, daily stories (news) are not just announced, but mostly edited in ways …
Pursuing its goal in treating hepatitis, Gilead Sciences (GILD) is at the finish line of clinical trials on …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
